FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2592484902> ?p ?o ?g. }

• W2592484902 abstract "Previous data from our institution showed that hypofractionated thoracic radiotherapy (HypoTRT) with concurrent etoposide/platinum chemotherapy yielded favorable survival in patients with limited-stage small cell lung cancer (LS-SCLC). The present study retrospectively compared the survival outcomes, failure patterns and toxicities between groups of LS-SCLC patients treated with conventionally fractionated thoracic radiotherapy (ConvTRT) or HypoTRT combined with chemotherapy. Medical records of LS-SCLC patients between January 2010 and December 2013 at Fudan University Shanghai Cancer Center were retrospectively reviewed. All patients treated with chemotherapy and ConvTRT (2 Gy per fraction daily, DT ≥ 56 Gy) or HypoTRT (2.5 Gy per fraction daily, DT = 55 Gy) were eligible for analysis. Progression-free survival (PFS) and overall survival (OS) were generated for different populations using the Kaplan-Meier method and compared using the log-rank test. Comparisons of failure patterns and toxicity were analyzed using the χ 2 test. A total of 170 patients treated with HypoTRT (n = 69) or ConvTRT (n = 101) were eligible for analysis. The median PFS and OS were 13.7 and 25.3 months, respectively, in the ConvTRT cohort, which was similar to the HypoTRT cohort (PFS 18.2 months, p = 0.991, and OS 27.2 months, p = 0.698), with a median follow-up of 30 months. Multivariate analysis revealed that PCI and TNM stage were prognostic factors for PFS and that PCI was prognostic for OS. The patterns of failure (stratified by local-regional recurrence, distant metastasis or both as first relapse) were similar between the dose cohorts (p = 0.693, p = 0.330, p = 0.572). Distant metastasis remained the main failure pattern. The brain was the most frequent remote failure site, followed by bone, liver and adrenal gland. PCI improved the 2-year survival rate from 46.1% to 70.0% and the 2-year PFS rate from 20.9% to 45.3%, respectively (p < 0.001). Grade ≥3 esophagitis and pneumonitis occurred in 9.9% and 11.9%, respectively, of the patients in the ConvTRT cohort and in 11.6% and 10.0%, respectively, of those in the HypoTRT cohort (p = 0.815). This retrospective analysis demonstrated that HypoTRT or ConvTRT combined with etoposide/platinum chemotherapy yielded statistically similar survival, treatment failure outcomes, and toxicity profiles. PCI correlated with improved PFS and OS." @default.
• W2592484902 created "2017-03-16" @default.
• W2592484902 creator A5001959086 @default.
• W2592484902 creator A5003986323 @default.
• W2592484902 creator A5005464911 @default.
• W2592484902 creator A5047138511 @default.
• W2592484902 creator A5065195779 @default.
• W2592484902 creator A5065503019 @default.
• W2592484902 creator A5076573459 @default.
• W2592484902 creator A5089564069 @default.
• W2592484902 date "2017-03-11" @default.
• W2592484902 modified "2023-09-25" @default.
• W2592484902 title "Hypo- or conventionally fractionated radiotherapy combined with chemotherapy in patients with limited stage small cell lung cancer" @default.
• W2592484902 cites W1554896841 @default.
• W2592484902 cites W158341068 @default.
• W2592484902 cites W1885320430 @default.
• W2592484902 cites W1905406155 @default.
• W2592484902 cites W1920090590 @default.
• W2592484902 cites W1973510243 @default.
• W2592484902 cites W1991585418 @default.
• W2592484902 cites W2006798053 @default.
• W2592484902 cites W2010674816 @default.
• W2592484902 cites W2020882823 @default.
• W2592484902 cites W2020917220 @default.
• W2592484902 cites W2021987821 @default.
• W2592484902 cites W2045359677 @default.
• W2592484902 cites W2074844270 @default.
• W2592484902 cites W2083817990 @default.
• W2592484902 cites W2093259073 @default.
• W2592484902 cites W2125430981 @default.
• W2592484902 cites W2131664752 @default.
• W2592484902 cites W2170552969 @default.
• W2592484902 cites W2308706242 @default.
• W2592484902 cites W2323020638 @default.
• W2592484902 cites W2339444986 @default.
• W2592484902 cites W2341745217 @default.
• W2592484902 cites W2531272164 @default.
• W2592484902 cites W3140025388 @default.
• W2592484902 doi "https://doi.org/10.1186/s13014-017-0788-x" @default.
• W2592484902 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5346226" @default.
• W2592484902 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28283034" @default.
• W2592484902 hasPublicationYear "2017" @default.
• W2592484902 type Work @default.
• W2592484902 sameAs 2592484902 @default.
• W2592484902 citedByCount "14" @default.
• W2592484902 countsByYear W25924849022017 @default.
• W2592484902 countsByYear W25924849022018 @default.
• W2592484902 countsByYear W25924849022020 @default.
• W2592484902 countsByYear W25924849022021 @default.
• W2592484902 countsByYear W25924849022022 @default.
• W2592484902 countsByYear W25924849022023 @default.
• W2592484902 crossrefType "journal-article" @default.
• W2592484902 hasAuthorship W2592484902A5001959086 @default.
• W2592484902 hasAuthorship W2592484902A5003986323 @default.
• W2592484902 hasAuthorship W2592484902A5005464911 @default.
• W2592484902 hasAuthorship W2592484902A5047138511 @default.
• W2592484902 hasAuthorship W2592484902A5065195779 @default.
• W2592484902 hasAuthorship W2592484902A5065503019 @default.
• W2592484902 hasAuthorship W2592484902A5076573459 @default.
• W2592484902 hasAuthorship W2592484902A5089564069 @default.
• W2592484902 hasBestOaLocation W25924849021 @default.
• W2592484902 hasConcept C126322002 @default.
• W2592484902 hasConcept C143998085 @default.
• W2592484902 hasConcept C146357865 @default.
• W2592484902 hasConcept C151730666 @default.
• W2592484902 hasConcept C167135981 @default.
• W2592484902 hasConcept C2776256026 @default.
• W2592484902 hasConcept C2776694085 @default.
• W2592484902 hasConcept C2778119113 @default.
• W2592484902 hasConcept C38180746 @default.
• W2592484902 hasConcept C45393284 @default.
• W2592484902 hasConcept C500558357 @default.
• W2592484902 hasConcept C509974204 @default.
• W2592484902 hasConcept C71924100 @default.
• W2592484902 hasConcept C72563966 @default.
• W2592484902 hasConcept C86803240 @default.
• W2592484902 hasConceptScore W2592484902C126322002 @default.
• W2592484902 hasConceptScore W2592484902C143998085 @default.
• W2592484902 hasConceptScore W2592484902C146357865 @default.
• W2592484902 hasConceptScore W2592484902C151730666 @default.
• W2592484902 hasConceptScore W2592484902C167135981 @default.
• W2592484902 hasConceptScore W2592484902C2776256026 @default.
• W2592484902 hasConceptScore W2592484902C2776694085 @default.
• W2592484902 hasConceptScore W2592484902C2778119113 @default.
• W2592484902 hasConceptScore W2592484902C38180746 @default.
• W2592484902 hasConceptScore W2592484902C45393284 @default.
• W2592484902 hasConceptScore W2592484902C500558357 @default.
• W2592484902 hasConceptScore W2592484902C509974204 @default.
• W2592484902 hasConceptScore W2592484902C71924100 @default.
• W2592484902 hasConceptScore W2592484902C72563966 @default.
• W2592484902 hasConceptScore W2592484902C86803240 @default.
• W2592484902 hasIssue "1" @default.
• W2592484902 hasLocation W25924849021 @default.
• W2592484902 hasLocation W25924849022 @default.
• W2592484902 hasLocation W25924849023 @default.
• W2592484902 hasLocation W25924849024 @default.
• W2592484902 hasOpenAccess W2592484902 @default.
• W2592484902 hasPrimaryLocation W25924849021 @default.
• W2592484902 hasRelatedWork W2083483287 @default.
• W2592484902 hasRelatedWork W2234839489 @default.

• next